Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06099093 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

StatusRecruiting
PhasePhase 4
Started2024-04-01
View on ClinicalTrials.gov ↗

Amendment history

2026-01-28
Study Status, Contacts/Locations v4
Primary completion date2025-12-01→2026-12-01
Completion date2025-12-01→2026-12-01
Study sitescontacts updated at 1 of 2 sites
2025-11-04
Study Status, Contacts/Locations v3
Study sitescontacts updated at 1 of 2 sites
2025-02-03
Study Status, Contacts/Locations v2
Primary completion date2024-12-01→2025-12-01
Study sitescontacts updated at 1 of 2 sites
2024-06-24
Not Yet Recruiting→Recruiting Study Identification, Study Status, Sponsor/Collaborators, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-04→confirmed 2024-04-01
Lead sponsorDana-Farber Cancer Institute→Brigham and Women's Hospital
Study sitesdetails revised at 2 of 2 sites
2023-10-19
Original filing
The purpose of this research study is to see how well an imaging test, called 18FDCFPyL prostate specific membrane antigen (PSMA) positron emission tomography (PET), can show the extent of prostate cancer when comparing to 68Ga-PSMA-11 PET/CT (another type of diagnostic scan for prostate cancer).
Trial Details
NCT Number NCT06099093
Lead Sponsor Brigham and Women's Hospital
Collaborators: Progenics Pharmaceuticals, Inc.
Conditions Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Carcinoma
Enrollment 30 participants
Start Date 2024-04-01
Primary Completion 2026-12-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-29